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a b s t r a c t
There is increasing evidence that human arylamine N-acetyltransferase type 1 (NAT1, EC
2.3.1.5), although first identified as a homologue of a drug-metabolising enzyme, appears to
be a marker in human oestrogen receptor positive breast cancer. Mouse Nat2 is the mouse
equivalent of human NAT1. The development of mouse models of breast cancer is impor-
tant, and it is essential to explore the biological role of mouse Nat2. We have therefore
produced mouse Nat2 as a recombinant protein and have investigated its substrate spe-
cificity profile in comparison with human NAT1. In addition, we have tested the effects of
inhibitors on mouse Nat2, including compounds which are endogenous and exogenous
steroids. We show that tamoxifen, genistein and diethylstilbestrol inhibit mouse Nat2. The
steroid analogue, bisphenol A, also inhibits mouse Nat2 enzymic activity and is shown by
NMR spectroscopy, through shifts in proton peaks, to bind close to the active site. A three-
dimensional structure for human NAT1 has recently been released, and we have used this
crystal structure to generate a model of the mouse Nat2 structure. We propose that a
conformational change in the structure is required in order for ligands to bind to the active
# 2008 Elsevier Inc.Open access under CC BY license.site of the protein.1. Introduction
Arylamine N-acetyltransferases (NATs, EC 2.3.1.5) have tradi-
tionally been identified as drug-metabolising enzymes
responsible for the metabolism of arylamines, arylhydrox-
ylamines and arylhydrazines. NATs were first identified in
man and a range of eukaryotes and have had an important
part to play in the early years of identification of pharmaco-
genetic variation in response to drug treatment [1].
The hydrazine drug isoniazid is polymorphically N-acety-
lated in humans to its therapeutically inactive form by the
human isoenzymenowknownas humanNAT2. There are two* Corresponding author. Tel.: +44 1865 271595; fax: +44 1865 271853.
E-mail address: edith.sim@pharm.ox.ac.uk (E. Sim).
0006-2952 # 2008 Elsevier Inc.
doi:10.1016/j.bcp.2007.12.012
Open access under CC BY license.human NAT isoenzymes: human NAT2, which metabolises
isoniazid, and human NAT1, which does not metabolise
isoniazid or other arylhydrazines [2], but does catalyse the
acetylation of a distinct but overlapping series of arylamines
[2]. The pattern of expression of the two human NAT genes
also differs. As a result of genome-wide microarray [3–12] and
proteomic studies [13], it is clear that human NAT1 is highly
expressed in oestrogen receptor positive breast cancer [14].
There is also evidence that the level of expression of human
NAT1 affects the growth of cultured breast cancer cells [13].
The role of the human NAT1 enzyme in breast cancer has
not been extensively explored, although it has previously been
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an inhibitor of human NAT1 [15–17]. It has also been
demonstrated that both human NAT1 and the oestrogen
receptor are down-regulated in tissues in which p53 is
mutated [5]. It appears that human NAT1 is a marker for
oestrogen receptor positive breast cancer, although informa-
tion is still accumulating on the relationship of this marker to
others, including the oestrogen receptor itself [14]. However, if
the human NAT1 enzyme is to be considered as a target for
breast cancer therapy, it is essential that there is a suitable in
vivo animal model for testing [18,19]. Mice represent the most
convenient animalmodels of disease. At present, the status of
mouse Nat2, the equivalent of human NAT1, in a model of
breast cancer has not been explored. We have previously
demonstrated that mouse Nat2 is expressed in the epithelial
cells lining the mammary ducts [20]. This is the same location
as the human NAT1 enzyme in normal breast tissue [13,21].
In order to provide a firm foundation for establishing such a
model, we have generated pure recombinant mouse Nat2 and
investigated its activity with a wide range of substrates and
the effects of a range of potential inhibitors, including
endogenous and exogenous steroids.2. Materials and methods
2.1. Chemicals
All chemicals were purchased from Sigma–Aldrich and all
molecular biology reagents were purchased from Promega,
unless otherwise stated.
2.2. Cloning and expression studies of mouse Nat2
The mouse Nat2 open-reading frame [22] was sub-cloned into
pET28b(+) (Novagen) using the compatible restriction enzyme
sites, NdeI and EcoRI. This allowed the production of
recombinant mouse NAT protein with an N-terminal His-
tag, for ease of downstream purification. The pET28b(+)
plasmid containing mouse Nat2 was transformed into Escher-
ichia coli strain JM109 and further transformed into Rosetta(-
DE3)pLysS (Novagen) after confirming the correct insert
sequence (DNA Sequencing Facility, Biochemistry, University
of Oxford). The positive transformant was grown in LB tomid-
log phase at 37 8C with shaking (180 rpm) and stored at 80 8C
with 10% (v/v) glycerol. Thawed glycerol stock (100 mL) was
used to inoculate fresh LB media (100 mL) supplemented with
kanamycin (30 mg/mL) and chloramphenicol (34 mg/mL) and
the culture was incubated at 37 8C for 16 h with shaking
(180 rpm). The starter culture was then diluted 50-fold into
freshLBmedia (2 L) supplementedwithkanamycin (30 mg/mL),
which was then incubated at 27 8C with shaking (180 rpm).
When the absorbance at 600 nm reached 0.7, the expression of
mouse Nat2 was induced by addition of isopropyl-b-D-
thiogalactopyranoside (IPTG) to a final concentration of
0.1 mM. The culture was grown for a further 16 h and the cells
were harvested by centrifugation (6000  g, 4 8C, 20 min). The
cell pelletwas resuspended in 20 mL lysis buffer (300 mMNaCl,
20 mM Tris–HCl (pH 8.0) containing 1 EDTA-free Complete
Protease Inhibitor (Roche)) and then stored at 80 8C.For expression of 15N-labelled mouse Nat2, the starter
culture was diluted 50-fold in 15N-labelled Standard-E. coli-
OD2 N medium (Silantes) supplemented with kanamycin
(30 mg/mL) and grown at 37 8C until the absorbance at
600 nm reached approximately 0.6. The cells were further
grown at 27 8C until the absorbance reached 0.7, when the
expression was induced with 0.1 mM IPTG. After induction for
17 h, the cells were harvested and stored as described for
unlabelled mouse Nat2.
The resuspended frozen cells were thawed at 37 8C and
sonicated on ice (25 cycles of 30 s on, 45 s off at 10 mm). The
soluble lysate was isolated from the cell debris by centrifuga-
tion (12,000  g, 4 8C, 20 min) and incubated (4 8C, 5 min) with
5 mL of Ni-NTA resin (Qiagen). The resin was sequentially
washed with lysis buffer containing increasing imidazole
concentrations in a step gradient at 4 8C (2 washes each of
10 mL of 0 mM, 10 mM, 20 mM, 50 mMand 100 mM imidazole).
Fractions containing hexa-histidine tagged Nat2 (His-Nat2),
were pooled and thrombin (5 U/mgNAT) was added to remove
the His-tag. After 16 h incubation at 4 8C, the protein sample
was dialysed against 20 mM Tris–HCl (pH 8.0), 1 mM dithio-
threitol (DTT), 1 mM EDTA buffer, and concentrated to 1 mg/
mL by centrifugation in a 15 mL concentrator (Amicon) after
addition of 5% (v/v) glycerol. Protein samples in 100 mL aliquots
were frozen in liquid nitrogen and stored at 80 8C.
Recombinant hamster Nat2 was expressed and purified as
previously described [23]. 15N-labelled hamster Nat2 was
grown and expressed as described for 15N-labelled mouse
Nat2 and purified by the same method as for the unlabelled
hamster Nat2.
The expression levels and activities of soluble Nat2 were
monitored by visualizing the levels of recombinant protein
expression on 12% acrylamide Tris–Glycine SDS-PAGE as well
as bymeasuring the rate of acetylation of 4-aminobenzoic acid
(PABA) as a substrate (see method below) [24].
2.3. Enzymic assays
2.3.1. Acetylation of arylamines
The rates of arylamine acetylation by NATs were determined
colorimetrically as previously described [25], but with minor
modifications. Each assay contained the enzyme, arylamine
substrate (see each figure legends for concentrations) and
AcCoA (400 mM) in a total volume of 100 mL in assay buffer
(20 mMTris–HCl (pH 8.0), 1 mMDTT). Initially, the enzyme and
substrate mixtures were pre-incubated at 25 8C for 5 min and
AcCoA was added to start the reaction. The reaction was
quenchedusing 20% (w/v) trichloroacetic acid (TCA) at different
time intervals. The stopped reaction was centrifuged
(16,000  g rpm, 10 min) to pellet the precipitated proteins.
Thestoppedreactionmixture (200 mL)wasadded to800 mLof5%
(w/v) 4-(N,N-dimethylamino)benzaldehyde (DMAB) in 9:1 acet-
onitrile:water to develop the colour. The absorption at 450 nm
was measured with a Hitachi U-2001 UV–vis spectrophot-
ometer, with the amount of residual substrate in the reaction
was determined by comparison with a standard curve.
2.3.2. Hydrolysis of AcCoA (free CoA production)
The rate of production of the free thiol Coenzyme A by NAT, in
the presence of a range of known NAT acetyl-acceptor
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dithio-bis(2-nitrobenzoic acid) (DTNB) as previously described
[2,26]. The substrate (500 mM) and purified recombinant NAT
were pre-incubated (25 8C, 5 min) in 96-well flat-bottomed
polystyrene plates (Costar1, Corning Inc.) in 20 mM Tris–HCl
(pH 8.0). AcCoA (400 mM) was added to start the reaction in a
final volume of 100 mL. The reaction was quenched with the
addition of 25 mL of guanidine–HCl solution (6.4 M guanidine–
HCl, 0.1 M Tris–HCl (pH 7.3)) containing 5 mM DTNB. The
absorbance at 405 nm was measured on a plate-reader
(Sunrise, Tecan). Assay buffer was used to replace substrate,
AcCoA or NAT for control reactions. The amount of CoA
produced in the assay was determined in comparison with a
CoA standard curve.
Substrate abbreviations used for the substrate selectivity
assays are as follows: aniline (ANL), 4-aminobenzoic acid
(PABA), 4-aminosalicylic acid (4AS), 5-aminosalicylic acid
(5AS), 4-chloroaniline (CLA), 4-bromoaniline (BRA), 4-iodoani-
line (IOA), 4-methoxyanline (ANS), 4-ethoxyaniline (EOA), 4-
butoxyanline (BOA), 4-hexyloxyaniline (HOA), 4-phenoxyani-
line (POA), 4-aminoveratrole (4AV), 2-aminofluorene (2AF), 4-
aminobenzoyl-L-glutamate (pABGlu), sulfamethazine (SMZ),
procainamide (PRO), 4-aminopyridine (APY), isoniazid (INH),
hydralazine (HDZ) and phenylhydrazine (PHZ). The stock
concentration of substrate was 100 mM dissolved in DMSO,
such that the final concentration of DMSOwas less than 5% in
the assays. DMSO only controls were carried out.
2.4. NMR spectroscopy
The 2D 1H-15N HSQC spectrum of mouse Nat2 was collected
using a 750 MHz NMR spectrometer (Department of Biochem-
istry, University of Oxford). The spectrum was collected at
20 8C for a sample containing 30 mg/mL of uniformly 15N-
labelled mouse Nat2 in 95% H2O/5% D2O 10 mM Tris buffer at
pH 7.0. Spectral widths of 12,500 and 2500 Hz were used in F2
and F1, respectively. The dataset contained 1024 and 128
complex points in t2 and t1, respectively.
1D 1H NMR spectra for hamster and mouse Nat2 were
collected at 20 8C using a jump-return sequence. ThisFig. 1 – Heterologous expression and purification of recombinant
affinity purification of mouse Nat2. Mouse Nat2 was produced
affinity chromatography. The purification gel shows expression
fraction; 3, unbound wash; 4, 0 mM imidazole (IMZ) wash; 5, 1 m
50 mM IMZ wash; 9, first 100 mM IMZ wash; 10, second 100 mM
(BioRad). Thrombin cleavage of His-Nat2. Purified His-Nat2 was
complete His-tag cleavage. Lanes: M, low-range molecular weig
treated, Nat2 (8 mg).sequence enabled the observation of HN peaks which
exchange to a significant extent with H2O. Spectra were
collected using a 600 MHz spectrometer using a sweep width
of 12,500 Hz. Unlabelled hamster andmouseNat2were used at
a concentration of 10 mg/mL in the buffer described above.
The titration of mouse Nat2 with bisphenol A was carried out
by stepwise addition of small volumes (5–20 mL) of a
concentrated solution of bisphenol A (100 mM in deuterated
DMSO) to the mouse Nat2 solution in the NMR tube. The
highest concentration of DMSO in the sample used was 2.8%.
DMSO alone had no effect on the NMR spectrum of mouse
Nat2 using concentrations up to 5%.3. Results
3.1. Cloning and expression of mouse Nat2
The mouse Nat2 was cloned into E. coli expression vector
pET28b(+) and expressed in E. coli Rosetta (DE3)pLysS with an
N-terminal hexa-histidine tag. The recombinant mouse His-
Nat2 was purified using immobilised metal affinity chromato-
graphy, using aNi-NTA column (Novagen), and eluted (Fig. 1a).
Pure Nat2 predominantly eluted in the 50 mM and 100 mM
imidazole washes. The hexa-histidine tag was readily
removed by thrombin digestion (Fig. 1b). The purified
recombinant Nat2 was active, readily catalysing the acetyla-
tion of PABA, a well-studied arylamine substrate of mouse
Nat2 [27] (Table 1). The enzyme was relatively stable, and the
enzymic activity was maintained (>85%) after incubation at
temperatures ranging between 4 8C and 25 8C over a 72 h
period.
3.2. Substrate specificity of mouse Nat2
To further characterise the purified recombinant mouse Nat2,
a panel of known NAT substrates (20 compounds) was tested
to determine the substrate selectivity of recombinant mouse
Nat2. In order to allow direct comparison with substrate
selectivity profile for human NAT1 and NAT2, the assay formouse Nat2 in E. coli. SDS-PAGE analysis of expression and
in E. coli Rosetta(DE3)pLysS strain and purified by Ni-NTA
of His-Nat2 at 34 kDa. Lanes: 1, whole cells; 2, soluble
M IMZ wash; 6, 10 mM IMZ wash; 7, 20 mM IMZ wash; 8,
IMZ wash; M, low-range molecular weight markers
incubated with thrombin (5 U/mg NAT) at 4 8C for 6 h for
ht marker (BioRad); 1, His-Nat2 only (8 mg); 2, thrombin-
Table 1 – Purification of mouse Nat2
Volume
(mL)
Protein
concentration (mg/mL)
Total
protein (mg)
Specific activity
(mmol/min/mg)
Total activity
(mmol/min)
Percentage
recovery
Culture 1000
Cell lysate* 15 35 531 5 2390
NAT containing IMZ
wash (50–100 mM)**
25 2 58 29 1682 70
Thrombin cleaved NAT** 25 1.9 47.5 28 1330 56
NAT activities were measured by determining the rate of acetylation of the arylamine substrate, PABA (100 mM), as described in Section 2.
Protein concentrations were measured by using the Bradford assay (*) and absorbance (**) at 280 nm (e280mNAT2 = 40920 M
1 cm1).
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previously described [2].
Mouse Nat2 shows high specific activities with a broad
range of arylamines, including PABA, 5AS, 4AS and 2AF (Fig. 2
and Supplementary Table 1). In contrast, mouse Nat2 shows
low specific activities against arylhydrazine substrates such as
HDZ, INH, and PHZ, and against arylamine drugs procaina-
mide and sulfamethazine (Fig. 2). This overall trend is in
agreement with the substrate selectivity observed in previous
studies with impure recombinant mouse Nat2 using a subset
of these compounds [22,27,28], although it is much less than
the activity observed towards these substrates with human
NAT2 (Fig. 2). There was low, yet measurable activity using
arylhydrazine substrateswith purifiedmouseNat2, which has
not been observed in previous studies using recombinant
mouse Nat2 expressed in a transient expression system [28].
Pure recombinant mouse Nat2 also readily acetylates 2-
aminofluorene, the substrate which has been used to identify
mouse strains carrying an active formofmouseNat2—the fast
acetylating C57Bl/6 strain, rather than the inactive form as is
found in the slow acetylating A/J strain which is unstable and
likely to be subject to rapid degradation [29].Fig. 2 – Comparison of the substrate specific activity profiles of m
specific activity profiles for mouse Nat2 (grey bars), human NAT
shown. The activity of mouse Nat2 was determined by measur
Purified mouse Nat2 (0.125 mg) was incubated with arylamine s
buffer (20 mM Tris–HCl (pH 8.0)) containing 0.5% (v/v) DMSO at 25
initial rates of reaction. All measurements were performed in t
relative to the most rapidly acetylated substrate. The human NA
defined in Section 2.The specific activity pattern of human NAT1 [2] overlaps
with the mouse Nat2 profile (Fig. 2), reconfirming that mouse
Nat2 is very similar to human NAT1 in substrate specificity.
Mouse Nat2 shows differences from the activity profile of
human NAT1, however. It appears that mouse Nat2 generally
has higher inherent specific activity than human NAT1 and
also acetylates arylhydrazines, when the acetylation of these
compounds by human NAT1 is not detected under the same
conditions [2].
3.3. Mouse Nat2 inhibition by steroidogenic compounds
It had been demonstrated, with extracts of tissues and cells
now known to express the human NAT1 gene, that tamoxifen
is an inhibitor of human NAT1 [15–17]. In view of the
relationship between the expression of human NAT1 and
oestrogen receptor positivity in breast cancer [14], we wished
to investigate the effects of steroidogenic compounds and
xenobiotic oestrogenic compounds, including tamoxifen, on
the activity of mouse Nat2.
From the inhibition study using a broad range of steroido-
genic compounds, it has been demonstrated that mouse Nat2ouse Nat2, human NAT1 and human NAT2. The substrate
1 (cross-hatched bars) and human NAT2 (black bars) are
ing the rate of CoA production, as described in Section 2.
ubstrate (each at 500 mM) and AcCoA (400 mM) in assay
8C. The specific activities were determined from the linear
riplicate and are expressed as meanW standard deviation
T1 and NAT2 data are taken from [2]. The abbreviations are
Table 2 – NAT inhibition by steroidogenic compounds
IC50 (mM)
Pregnelone >100
17-Hydroxy-progesterone >500
Androsteinedione >500
Testosterone >500
Estrone 370  10
17-Hydroxy-b-estradiol 55  5
The steroidogenic compounds which have shown inhibition
against mouse Nat2 (Supplementary Fig. 1) were further investi-
gated and their IC50 values were determined by varying the
inhibitor concentrations (1–500 mM) under the same experimental
conditions as described in Supplementary Fig. 1.
Table 3 – Mouse Nat2 inhibitory concentration (IC50) of xenob
Xenobiotic estrogens
Tamoxifen
4-OH tamoxifen
Diethylstilbestrol (E)-3,4-Bis(4-hydroxyphenyl)-3-hexene
Zearalenone
Alpha-Zearalenol
Beta-Zearalenol
Bisphenol A
Geni stein
Half-maximal inhibitory concentrations of xenobiotic oestrogens against
Fig. 1).
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hydroxy-b-estradiol identified as the most potent inhibitor
(Table 2 and Supplementary Fig. 1). This was substantiated by
the inhibition ofmouseNat2 activity by xenobiotic oestrogens,
such as tamoxifen, and the IC50 values for these inhibitors are
shown in Table 3. The phytoestrogens genistein, alpha-
zearalenol and the synthetic oestrogen diethylstilbestrol show
similar potency of mouse Nat2 inhibition to 17-hydroxy-b-
estradiol, tamoxifen and 4-hydroxy tamoxifen. Bisphenol A
was also shown to be an inhibitor of mouse Nat2, albeit with
lower potency than some of the other compounds tested. One
key practical advantage of using bisphenol A as an inhibitor is
the improved solubility of this compound relative to the other
phytoestrogens and steroids.iotic oestrogens
Structures IC50 mNAT2 (mM)
57  3
65  15
50
220  10
70  10
450  10
290  10
45  5
mouse Nat2 were measured as previously described (Supplementary
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Until recently, there has been no structural information on
eukaryotic NAT enzymes. However, recently the three-
dimensional structure of a human NAT1 mutant (Phe/Ser
substitution at position 125) was determined by X-ray crystal-
lography (PDB accession code: 2IJA [30]). A non-mutated
human NAT1 crystal structure has also been deposited in
which the active-site cysteine residue was modified to S-(2-
anilino-2-oxoethyl)-cysteine (PDB accession code: 2PQT). It is
considered likely that both themutation of residue 125 and the
modification of the active-site cysteine residue stabilise the
structure of the human enzyme, because thousands of
attempts to generate a crystal from the native human NAT1
protein have been unsuccessful (A. Kawamura, unpublished
results). The structure of human NAT1 is illustrated in
comparison with the NAT from M. smegmatis (Fig. 3). The
eukaryotic proteins contain a loop between the second and
third domains. This inter-domain loop is not present in their
prokaryotic counterparts [31], as highlighted in Fig. 3. It is
interesting to note that in the structure of the human NAT1
enzyme, this inter-domain loop is folded back over the active
site. Likewise, the C-terminus is shown to be folded over the
active-site cleft. These observations indicate that a conforma-
tional change in the protein may be required to allow the
substrates to access the active-site cysteine residue. However,Fig. 3 – Comparison of the crystal structures of NAT from M.
smegmatis (MSNAT) and human NAT1. The surface shown
was calculated from the MSNAT crystal structure (PDB
accession code 1GX3), and the human NAT1 crystal
structure F125S mutant (PDB accession code 2IJA) is
shown in ribbon format. The C-terminus and inter-
domain loop region of human NAT1 protrude from the
eukaryotic protein core, and both of these protein regions
block the prokaryotic NAT active site. The C-terminus of
human NAT1 is found in the region termed the ‘b-site’
[47].a structure of human NAT2 with coenzyme A bound has also
been deposited (PDB accession code: 2PFR), and the position of
the coenzymeA is such that the C-terminus and inter-domain
loops regions are not significantly changed. This is in contrast
to the recently reported structure of Mycobacterium marinum
NAT in complex with coenzyme A [32]. In this bacterial NAT,
the C-terminus is shorter than in the eukaryotic structures,
and there is no inter-domain loop, and the ligand is found in
the space where these regions are located in the eukaryotic
structure.
We have generated a structural model of the mouse Nat2
protein, whose amino acid sequence is over 80% identical to
human NAT1, by using the program Modeller 8v2 [33]. Fig. 4
shows the structural model of mouse Nat2 and a comparison
of the mouse Nat2 and human NAT1 protein structures. The
two structures share 1191 equivalent atoms, over which the
root mean squared deviation is 0.75 A˚. In mouse Nat2, as in
human NAT1, the inter-domain loop and the C-terminus
occlude the active site. Despite the evidence for coenzyme A
binding to human NAT2 without major conformational
rearrangement of the C-terminus and inter-domain loop
regions, it has not been possible to perform ligand docking
into the mouse Nat2 or human NAT1 structures without
disturbing these regions of the protein structure. Therefore, it
remains possible that the inter-domain loop regions and C-
termini of the eukaryotic NAT proteins are conformationally
flexible, in order to accommodate substrate or inhibitor
binding.
3.5. NMR studies
NMR studies are ideal for investigating protein interactions
with substrates and inhibitors in solution. Therefore, we have
generatedmouse Nat2 uniformly labelled with 15N to allow 2D
NMR investigations of the protein. The 2D 1H-15N HSQC
spectrum of mouse Nat2 is shown in Fig. 5; this spectrum
contains a peak for each backbone amide (1HN-15N) and
additional peaks from the side chains of Asn, Gln and Trp. The
HSQC spectrum is well resolved, as expected for a compact
globular structure, and some cross peaks are relatively sharp
for a 30 kDa protein, this may indicate some flexibility
between the domains of mouse Nat2 or the presence of
mobile loops. The HSQC spectrum of mouse Nat2 has been
compared with the corresponding spectrum from hamster
Nat2 for which a full assignment is available [34]. The pattern
of peaks in the HSQC spectra is extremely similar for the two
homologous proteins; this allows some peaks observed in the
mouse Nat2 spectrum to be assigned on the basis of the
hamster Nat2 spectrum.
The downfield region of the 1H 1D spectra, collected with a
jump-return sequence, of mouse and hamster Nat2 also show
a similar pattern of peaks (Fig. 6A and B). The four peaks are
compared in Table 4, together with their assignments. Two of
the peaks (2 and 3) have been assigned previously for hamster
Nat2 and can be assigned in themouse spectrumbyhomology;
these correspond to strongly hydrogen bonded tryptophan
indole groups: the tryptophan associated with the P-loop
(Trp132, see Fig. 7) and Trp67, which is located adjacent to the
active-site Cys68, and appears to have a structural role. The
stronghydrogen bonds are likely to be responsible for the large
Fig. 4 – (a) and (b) The structure of mouse Nat2. The mouse Nat2 protein structure was produced by homology modelling
with the program Modeller 8v2 [33]. The human NAT1 crystal structure (PDB code 2IJA) was used as a template, and the
amino acid sequences of human NAT1 and mouse Nat2 were aligned with the program ClustalW [48]. The mouse Nat2
ribbon structure is shown in green. The ribbon structures of the inter-domain loop region and C-terminal hexapeptide
residues (residues 168–184 and 285–290) are shown in dark green, and the active site catalytic triad (Cys68, His107 and
Asp122) residues are shown in ball and stick representation. The pdb file of the mouse Nat2 homology model is available
upon request. The figure was produced with Aesop, as previously described [49]. (c) and (d) A comparison of the human
NAT1 crystal structure (PDB code 2IJA) and the mouse Nat2 homology model. The human NAT1 crystal structure is shown
in blue and the mouse Nat2 model is shown in green. The two proteins share 82% identity at the amino acid level. Over
1191 equivalent atoms, the two structures have a root mean squared deviation of 0.75 A˚. The catalytic triad residues for
both proteins are shown in ball and stick representation. The views in (b) and (d) were obtained by rotating the structures
shown in (a) and (c) by 308. (For interpretation of the references to colour in this figure legend, the reader is referred to the
web version of the article.)
b i o c h em i c a l p h a rma co l o g y 7 5 ( 2 0 0 8 ) 1 5 5 0 – 1 5 6 01556downfield shifts of these tryptophan peaks compared to
random coil values (9.5 ppm). The two remaining peaks (1
and 4) are assigned to the imidazole 1HN of histidine on the
basis of 15N decoupling experiments; these peaks have not
been assigned previously for hamster Nat2. The side chain 1HN
groups of histidine are usually not observed by NMR,particularly at pH 7, due to their rapid exchange with solvent
protons. The observation of these peaks indicates that the
histidine residues are probably buried within the protein and
that the side chain 1HN are involved in hydrogen bonds.
Analysis of the homology model of mouse Nat2 suggests that
at least one of these peaks might arise from the active site
Fig. 5 – 750 MHz 2D 1H-15N HSQC spectrum of mouse Nat2.
Fig. 6 – The downfield region of the 1D 1H NMR spectra of
(A) mouse and (B) hamster Nat2 collected using a jump-
return pulse sequence. These peaks arise from the indole
HN of two tryptophan residues (peaks 2 and 3, Trp67 and
Trp132 respectively) and from imidazole HN of histidine
(peaks 1 and 4, His).
b i o c h em i c a l p h a rma c o l o g y 7 5 ( 2 0 0 8 ) 1 5 5 0 – 1 5 6 0 1557histidine, His107. The homology model of mouse Nat 2
indicates that the side chain of His107 is involved in two
hydrogen bonds in the active site and is the least accessible to
solvent. In addition, recent enzymological studies with
hamster Nat2 have confirmed that the active-site cysteine
and histidine residues exist as a thiolate-imidazolium ion pair
[35], in which the histidine has two tightly bound and H-
bonded protons.
3.6. Interaction of mouse Nat2 with exogenous steroid
inhibitors
In order to probe the molecular interactions of mouse Nat2
and the exogenous steroid inhibitors, wehave investigated the
effect of bisphenol A on the 1D 1H NMR spectrum of mouse
Nat2 (Figs. 8 and 9). The observation of changes in chemical
shift for particular amino acid residues which result from the
addition of a ligand are usually interpreted as an indication
that these residues are located in close proximity to the ligand-
binding site. When bisphenol A was titrated into a solution of
mouse Nat2, the two downfield histidine peaks (1 and 4,
Table 4) were observed to shift by more than 0.05 ppm (Fig. 9);
peak 1 shifts downfield by0.12 ppm and peak 4 shifts upfield
by 0.08 ppm in the presence of 8 equivalents of bisphenol A.
Additional small shifts were also observed for the side chain
HN of Trp67 and Trp132 (Fig. 9). The observation of progressive
changes in chemical shift upon addition of bisphenol A
indicates fast exchange on the NMR timescale; this would be
expected given the relatively weak affinity of mouse Nat2 for
this ligand (IC50 = 290  10 mM).Wehave postulated above thatTable 4 – Summary of peaks observed in the downfield region
Peak Hamster Nat2
1H d (ppm)
Mouse Nat2
1H d (ppm)
1 12.64 12.57
2 11.70 11.80
3 11.38 11.26
4 11.13 10.79at least one of the histidine peaks arises from the active-site
histidine, His107; therefore, these results show that binding of
bisphenol A is likely to take place in close proximity to the
active site of mouse Nat2.4. Discussion
The possibility that human NAT1 may serve as a marker for
sub-dividing populations of different breast cancers is intri-
guing. It may also be that human NAT1 will find a role as a
target for breast cancer therapies. In order to exploit these
findings fully, it will be essential to have an animal model.
There have been, for a long time, suggestions that human(10.5–13 ppm) of the spectra of hamster and mouse Nat2
Mouse Nat2
15N d (ppm)
Assignment
170.2 Histidine side chain HN
132.0 Trp67 indole HN
128.6 Trp132 indole HN
165.2 Histidine side chain HN
Fig. 7 – The mouse Nat2 homology model, based on the
crystal structure of human NAT1, showing the position of
Trp132 relative to the active-site triad (shown in ball and
stick representation). The putative phosphate-binding P-
loop is shown.
Fig. 8 – The downfield region of the 1D 1H NMR spectra
obtained in a titration of mouse Nat2 with bisphenol A.
Spectra collected with 0–8 equivalents of bisphenol A are
shown. Peaks are observed to shift and to broaden as
increasing amounts of bisphenol A are added; this
broadening may indicate chemical exchange within the
bound protein. Some precipitation of protein was
observed with 8 equivalents of bisphenol A, which is
likely to account for the decrease in peak intensity in this
spectrum.
b i o c h em i c a l p h a rma co l o g y 7 5 ( 2 0 0 8 ) 1 5 5 0 – 1 5 6 01558NAT1 has an endogenous role. The mouse equivalent of
human NAT1 is mouse Nat2. Genetic deletion of mouse Nat2
has not created an overt phenotype; however, some of these
studies inmice indicate thatNat2 deletion gives rise to skewed
sex ratios both on mixed [36] and pure [37] genetic back-
grounds, indicating a gender-dependent phenotype, discern-
able at the population level, that is consistent with a role in
endocrine function. There is now also clear evidence that
mouse Nat2 has a role in vivo in folate catabolism [38]. These
studies, together with the data on human NAT1 and breast
cancer, are intriguing and are likely to provide clues as to the
endogenous role of NAT1. The data presented increases the
knowledge of mouse Nat2 in comparison with human NAT1
and reinforce the notion thatmouseNat2 is a good homologue
of human NAT1. Mouse Nat2 has a similar substrate specific
activity profile to human NAT1.
The inhibition studies show thatmouseNat2 is inhibited by
endogenous steroids and, like human NAT1, is inhibited by
tamoxifen. Bisphenol A, which is used for making polycarbo-
nates [39], has been reported to activate the oestrogen receptor
[40]. Like tamoxifen, it is also an inhibitor of mouse Nat2. We
have used bisphenol A to look at the binding of an oestrogenic
stimulatory compound to mouse Nat2 and show by NMR that
bisphenol A interacts with mouse Nat2 close to the active site
region. These studies could not be done directly with
tamoxifen because of the high concentrations of protein
(andhence ligand) required for NMRexperiments underwhich
conditions tamoxifen is insoluble. Both endogenous and
xenobiotic oestrogens have been shown to modify breast
cancer risk, and tamoxifen is widely used for breast cancertherapy (reviewed in [41]). The effect of different synthetic or
natural oestrogens on cell proliferation has been analysed
directly, in breast cancer cell lines, and in gene expression
studies [41–44]. Although the dose–response curves for
different oestrogenic compounds vary with the assay system,
bisphenol A is generally less active than tamoxifen, genistein
or diethylstilbestrol, which reflects the order of potency of
mouse Nat2 inhibition. Circulating plasma concentrations of
the phytoestogen genistein have been found to be as high as
18 mM after a soy-based meal [45], and intratumoral levels of
tamoxifen can reach micromolar concentrations [46].
Whether the effects on inhibition of Nat2 activity in vitro
may be physiologically relevant for breast cancer prevention
or therapy will require further analysis.
These studies pave the way for investigation of the role of
mouse Nat2, the human NAT1 homologue, in studies of
oestrogen receptor positive breast cancer. This is particularly
relevant in view of the observation that mouse Nat2 is located
histologically in the mammary gland epithelial cells [20]. The
structural studies also provide a rational basis for identification
Fig. 9 – Titration of mouse Nat2 with bisphenol A. The
magnitudes of changes in chemical shift observed for the
four downfield shifted peaks are shown as a function of
the amount of added bisphenol A. The largest shifts are
observed for peaks 1 (filled circle) and 4 (open square)
which arise from histidine; smaller shifts are observed for
peaks 2 (open triangle) and 3 (filled triangle).
b i o c h em i c a l p h a rma c o l o g y 7 5 ( 2 0 0 8 ) 1 5 5 0 – 1 5 6 0 1559of mouse Nat2 inhibitors. We have recently screened a 5000-
strong compound library using human NAT1, human NAT2,
mouse Nat1 and mouse Nat2; from these studies, several
compounds been have identified which are potent and specific
inhibitors of human NAT1 and its mouse homologue, Nat2. An
accumulation of information on the eukaryoticNATproteins at
a structural level will allow further development of chemical
tools for investigation of the role of thismarker in breast cancer
in humans, and its potential in animal models.
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